Entacapone D10
| Product Name | Entacapone D10 |
|---|---|
| Alternate Names | Entacapone Stable Isotopes, Stable Isotopes of Entacapone |
| CAT No. | CS-O-06584 |
| CAS No. | 1185241-19-3 |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 315.35 g/mol |
| Mol. For. | C₁₄H₅D₁₀N₃O₅ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Entacapone |
| Purity | Not less than 90 % |
| Therapeutic | Anti-Parkinsons |
| Smileys | O=C(N(C([2H])([2H])C([2H])([2H])[2H])C([2H])([2H])C([2H])([2H])[2H])/C(C#N)=C/C1=CC([N+]([O-])=O)=C(O)C(O)=C1 |
| Canonical Smiles | CCN(CC)C(=O)C(=CC1=CC(=C(C(=C1)O)O)[N+](=O)[O-])C#N |
| InchIKey | JRURYQJSLYLRLN-YFIMXNTNSA-N |
| Inchl | InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+/i1D3,2D3,3D2,4D2 |
| IUPAC | (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-bis(1,1,2,2,2-pentadeuterioethyl)prop-2-enamide |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Entacapone D10 is a potent and selective inhibitor of catechol-O-methyltransferase (COMT), an enzyme that plays a crucial role in the metabolism of catecholamines such as dopamine, epinephrine, and norepinephrine. Entacapone D10 is used in the treatment of Parkinson's disease, a neurodegenerative disorder that affects the dopamine-producing neurons in the brain.
When Entacapone D10 is administered orally, it is rapidly absorbed and reaches peak plasma concentrations within 1-2 hours. The drug is extensively metabolized in the liver, primarily via glucuronidation and oxidation, and is excreted in the urine. The half-life of Entacapone D10 is approximately 2-3 hours, and it is typically administered three times per day in combination with levodopa and a dopamine agonist.
Entacapone D10 works by inhibiting the activity of COMT, which increases the concentration of levodopa in the brain and prolongs its effectiveness. Levodopa is a precursor to dopamine, and it is converted to dopamine in the brain. By increasing the concentration of levodopa in the brain, Entacapone D10 helps to alleviate the symptoms of Parkinson's disease, including tremors, rigidity, and bradykinesia.
Overall, Entacapone D10 is a valuable tool in the treatment of Parkinson's disease, and its chemical properties and mechanism of action make it an effective and well-tolerated medication.
Get an Instant Quote
Related Compounds
Entacapone-d10 (cis) |